A Phase 2 interventional study of 68Ga-NODAGA-E[c(RGDyK)]2 in Chronic Ischemic Heart Disease, sponsored by Rigshospitalet, Denmark. Not yet recruiting at 1 site in Denmark. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-11-21.
Sponsored by Rigshospitalet, Denmark · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark — 3 open to participants now, 3 under way, none of them phase 3. Myocardial Ischemia · Rigshospitalet, Denmark.
Among the 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 2 in phase 2, and was the 9th registered.
1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.
Browse Myocardial Ischemia studies →3 of the 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark are open now, in 1 country. Recruiting first, the newest first:
Rigshospitalet, Denmark · Sites in Denmark
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
By country, each count listing its studies:
Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 1 · Phase 4 1
First in 1997; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 42 is below the median of 116 across 622 interventional studies indexed under Myocardial Ischemia.
Median enrollment 54 across the 12 interventional studies, 24 across the 1 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Rigshospitalet, Denmark is the lead sponsor of 1,004 studies on the registry; 173 are open to participants now.
1 of the studies in Myocardial Ischemia by Rigshospitalet, Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06033014Rigshospitalet, DenmarkClinical Implementation of a Novel Decision Support Tool in Patients With Ischemic Heart Disease | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim is to examine the expression of αvβ3 integrin using a novel selective radiotracer in patients with chronich ischemic heart disease and investigate if it is a suitable tool for predicting myocardial recovery and thus prognosis after intervention.
Ischemic heart disease is worldwide the single most frequent cause of death. The number of patients surviving acute myocardial injury is increasing due to improved acute treatment. However, after the initial repair, the tissue undergoes a remodeling phase to compensate for the damaged area. This re-modeling phase can change the structure end geometry of the heart resulting in lower ejection fraction, leading to cardiac dysfunction, which eventually leads to heart failure. Ischemic heart disease is most commently caused by arteriosclerosis of the coronary artery.
If chronic ischemic heart disease is left untreated, it will lead to symptoms to the patient. These symptons occur when the myocardiel oxygen demand exceeds the oxygen provided, due to coronary occlusion.
If the heart suffers from ischemia, the tissue reacts strongly to the hypoxia. The body will as a compensatory mechanism create new vessel to provide the tissue with oxygen. This is known as the biological process of angiogenesis. This complex process involves different angiogenic and pro-fibrotic transcription factors that initiate the restoration of capillaries by sprouting from the existing endothelial cells in response to hypoxia.
Integrin αvβ3 is a transmembrane cell surface receptor that is markedly upregulated in states of angiogenesis. It facilitates migration and proliferation and thereby allowing cells to respond to extracellular environment. Integrin αvβ3 is thus a key player in the angiogenic process. The integrin αvβ3 has a binding site for an RGD peptide (Arg-Gly-Asp motif) and this can be targeted by PET tracers.
RGD-based PET tracers have been shown to accumulate at the site of myocardial necrosis in both human and animal studies. The uptake before interventions may correlate to recovery of cardiac function and thus serve as a prognostic marker after intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV. two times. 14-21 days before intervention and 30-35 days after intervention
Drug: 68Ga-NODAGA-E[c(RGDyK)]2
200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV. two times. 14-21 days before intervention and 30-35 days after interventionintervention
Drug: 68Ga-NODAGA-E[c(RGDyK)]2
200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.
Also known as: RGD-PET
To evaluate myocardial angiogenesis
Analysing change in uptake of 68Ga-NODAGA-E\[c(RGDyK)\]2 Positron Emission Tomography after intervention
Time frame: 30-35 days
Correlation between 68Ga-NODAGA-E[c(RGDyK)]2 and myocardial perfusion
Correlation between uptake of 68Ga-NODAGA-E\[c(RGDyK)\]2 and change in myocardial perfusion after intervention using Rubidium 82 Positron Emission Tomography
Time frame: 30-35 days
Correlation between 68Ga-NODAGA-E[c(RGDyK)]2 and functional recovery
Correlation between uptake of 68Ga-NODAGA-E\[c(RGDyK)\]2 and functional recovery using Magnetic Resonance after intervention
Time frame: 30-35 days
Correlatino between 68Ga-NODAGA-E[c(RGDyK)]2 and viability
Correlation between uptake of 68Ga-NODAGA-E\[c(RGDyK)\]2 and viability using Flour-Deoxy-Glucose Positron Emission Tomography after intervention
Time frame: 30-35 days
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2024; primary completion for Dec 2025, 23 months later.
Of 16 phase 2 interventional studies under Myocardial Ischemia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's planned 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.